Symposium Addresses Unique Needs of Young Adults with Rheumatic Diseases PDF Print E-mail
Wednesday, 05 October 2011 07:55

The Arthritis Foundation is sponsoring the 2nd Annual Arthritis in PrimeTime symposium on Saturday, October 22 at the Long Beach Renaissance Hotel in Long Beach. This premier educational and motivational event fosters active and fulfilling lives for young adults (ages 17-45 years old) affected by arthritis, fibromyalgia, lupus, scleroderma, ankylosing spondylitis and other chronic diseases. 



The event's theme is "Making My Work Work–"Work" being broadly defined as college, disability, life transitions, home-making or career. Led by top medical experts and advocates, informational sessions will educate hundreds of participants with chronic diseases about diverse lifestyle issues (including transition from college to the job market, workplace success, social relationships and health insurance issues), as well as research updates and medical treatments for pain management.  

"Most people do not know that arthritis is the #1 cause of work disability in the United States," said Arthritis in PrimeTime chair, Amye Leong, M.B.A. "Arthritis in PrimeTime is a positive, motivating event designed to help over 11 million young people affected with arthritis and other rheumatic diseases lead active, productive lives."  Ms. Leong, who was wheelchair-bound by rheumatoid arthritis, is today the international spokesperson for the United Nations Bone and Joint Decade.

Arthritis in PrimeTime is made possible through the Jane Wyman Trust and Pfizer, and is conducted in partnership with LupusLA, National Fibromyalgia Association, Scleroderma Foundation, Spondylitis Association of America, and Arthritis Introspective. 

The symposium begins at 9 a.m., and ends with an inspirational closing address by Matt Iseman, M.D., renowned comedian and host of Style Network's "Clean House."  Tickets are $25 each or $40 per couple. 

For more information or to register for this event, visit www.arthritisinprimetime.org or contact Jennifer Ziegler at the Arthritis Foundation at 323.954.5760 Ext. 243.

Source: PRNewswire


 
More articles :

» Endothelin Antagonists Present Great Promise

One of the most intriguing developments in recent medical science is the discovery of the human chemical endothelin (ET). Since its detection in 1988, over 22,000 scholarly articles (about 3 per day) have been published on the subject, a new class...

» HSCT Benefits In Early Diffuse Cutaneous Systemic Sclerosis

Initial results from an international, investigator-initiated, open label phase 3 trial, presented at EULAR 2012, indicate that haematopoietic stem cell transplantation (HSCT) results in better long-term survival than conventional treatment for...

» Promedior Announces Publication of New Research Demonstrating Pentraxin-2/SAP is a Potent Inhibitor of Pulmonary Fibrosis

Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today the publication of collaborative research in the International Journal of Biochemistry and Cell Biology...

» Unite Against Scleroderma

On May 1st 2011, the would be holding its first annual "Unite Against Scleroderma" Walk around the Queen's Park Savannah, Port Of Spain. It is our aim to help raise awareness of this rare autoimmune disease and the funding needed to aid those who...

» Comprehensive Report on the Global State of Autoimmune Diseases Released

A groundbreaking new report from the (AARDA), examining the current state of autoimmune disease (AD) and its economic and social impact globally and in the U.S., was released today at the National Autoimmune Diseases Summit:  The Global State...

» More Vitamin D?

Andrew Weil, M.D., recently recommended that we raise our intake of 1,000 IU of vitamin D per day to 2,000 IU per day. Why?According to Dr. Weil, we have known for many years that we need vitamin D - it is actually a hormone - to facilitate calcium...